CEO Executive AssistantMarket access has become one of the most strategically important functions in pharmaceutical organizations. Formulary positioning, payer negotiations, health technology assessments, and patient access programs determine whether a product’s clinical efficacy translates into commercial success and patient benefit.
For pharma CEOs, market access requires strategic oversight without operational immersion. This framework clarifies how to delegate effectively.
Why This Matters for Pharmaceutical CEOs
Pharmaceutical organizations face administrative demands that generic tools are not built to address. When your executive assistant resources are not calibrated to your operating environment, the gap shows up as hiring delays, poor placement outcomes, and ongoing management friction that consumes time you cannot recover.
The pharmaceutical ceos who build strong support structures consistently outperform those who use generic approaches. They hire faster, retain EA talent longer, and reclaim more productive hours per week. The compound return on a well-managed support relationship is one of the most underrated performance advantages available at the senior level.
Building that advantage starts with using the right resources for your sector. A framework designed for pharmaceutical executive support already accounts for the terminology, workflows, and compliance requirements specific to your environment. You spend time applying it rather than adapting a generic template to fit.
The CEO’s Market Access Strategic Role
Pricing strategy approval. Launch pricing, net pricing strategy, and major pricing architecture decisions require CEO-level approval because they have profound commercial, financial, and reputational implications.
Major payer strategy decisions. The overall payer engagement strategy, including decisions about how aggressively to pursue formulary positioning and what rebate levels to accept, is a CEO-level strategic decision.
Public and policy positioning on pricing. In environments of high public scrutiny on pharmaceutical pricing, the CEO is the primary organizational voice. Pricing communications, responses to Congressional inquiries, and public statements on patient access require CEO ownership.
Health technology assessment strategy. For products subject to major HTA evaluations (NICE, G-BA, ICER), the strategy for data presentation, economic modeling priorities, and negotiating positions has real commercial implications requiring CEO alignment.
Market access investment decisions. Staffing the market access and HEOR functions, funding patient assistance programs, and investing in real-world evidence generation are budget decisions requiring CEO approval.
Market Access Delegation Framework
To the VP of Market Access or Chief Payer Officer
Payer contracting operations. Negotiating rebate contracts, managing PBM relationships, and administering payer agreements are market access team responsibilities.
Formulary management. Tracking formulary status across health plans, managing formulary challenges, and pursuing coverage expansions are market access operations.
HTA submission preparation. Developing HEOR models, preparing HTA dossiers, and managing HTA submission processes are HEOR and market access functions.
Patient assistance program administration. Co-pay assistance programs, patient support programs, and hub services for complex products are market access and patient services functions.
Managed markets data analytics. Tracking formulary coverage, plan performance, gross-to-net analysis, and payer market analytics are market access analytics responsibilities.
State Medicaid contracting. Managing Medicaid best price calculations, Medicaid rebate administration, and state supplemental rebate negotiations are market access and finance functions.
To the HEOR Team (Health Economics and Outcomes Research)
Economic modeling. Budget impact models, cost-effectiveness models, and value-based contracting models are HEOR functions.
Real-world evidence strategy. Designing RWE studies, managing RWE data partnerships, and analyzing RWE datasets are HEOR responsibilities.
HTA scientific submissions. Preparing economic and outcomes evidence for HTA submissions is an HEOR function.
Value story development. Translating clinical and economic evidence into payer-facing value propositions is an HEOR and market access function.
To the Pricing Team
Internal pricing analytics. Conducting price sensitivity analyses, competitive pricing benchmarking, and gross-to-net modeling are pricing team functions.
International reference pricing management. Monitoring international reference pricing implications and managing launch sequencing to optimize price protection are pricing operations functions.
Pricing governance administration. Managing the internal pricing governance process, including pricing committee scheduling and documentation, is a pricing operations function.
Building Market Access Delegation Infrastructure
Market Access Launch Readiness Process
A structured launch readiness process for market access ensures that formulary strategy, payer contracting frameworks, patient access programs, and HEOR evidence are in place before product launch. The market access team manages this process with CEO review at key milestones.
Monthly Market Access Dashboard
A monthly market access report covers:
- Commercial formulary coverage by plan type versus target
- Net price realization versus plan
- Patient assistance program utilization
- HTA submission and negotiation status for key markets
- Competitive formulary positioning
Pricing Governance Committee
A pricing governance committee with cross-functional representation (market access, commercial, finance, legal) reviews pricing decisions within defined authority thresholds. The CEO participates in major pricing decisions that exceed committee authority.
For pharma CEOs managing market access alongside commercial and business development, delegation guide for pharma CEO: commercial operations covers the commercial operations complement to market access strategy.
Broader pharmaceutical executive delegation frameworks are addressed in what pharmaceutical biotech CEOs delegate to their chief of staff.
What Makes a Great Delegation Framework
- Explicit scope boundaries: Clear frameworks define what is delegated, what decisions remain with the executive, and what triggers require immediate escalation.
- Accountability structure: Strong frameworks assign ownership with defined deliverables and review cadences, not just task lists without deadlines or standards.
- Information flow clarity: Effective frameworks specify what information flows to the executive, at what frequency, and in what format, preventing both overload and dangerous blind spots.
- Progressive autonomy: The best frameworks build deliberate stages of increasing independence as trust and demonstrated competence grow.
- Feedback integration: Strong frameworks include structured review cycles that improve delegation quality over time rather than locking in initial assumptions.
Common Mistakes to Avoid
The most common delegation failure is delegating tasks without delegating context. Telling a direct report what to do without explaining why produces technically correct but strategically misaligned execution that requires constant correction.
The second most common failure is inconsistent follow-through. Executives who delegate and then disappear until the deadline create an environment where the team cannot raise issues early enough to resolve them before they become real problems.
- Delegating tasks without explaining the desired outcome and strategic context
- Omitting escalation criteria from the initial delegation conversation
- Checking in so infrequently that problems surface at the deadline rather than early
- Delegating decisions that require executive judgment without a clear escalation path
Setting Up Your Delegation System
Effective delegation requires documentation before execution. Before handing off any function, write down the desired outcome, the decision authority granted, the reporting cadence expected, and the conditions that require escalation. This documentation takes 15 minutes per function and prevents weeks of corrective work later.
Start with two or three functions that are clearly delegable – calendar management, meeting coordination, routine reporting. Build confidence and trust through consistent execution on lower-stakes functions before delegating higher-stakes decisions. Progressive delegation compounds: each successful handoff increases the EA’s operational fluency and reduces the CEO’s oversight burden.
Review your delegation scope quarterly. As your organization grows, the administrative complexity grows with it. A delegation framework that fit your organization at 30 people may be badly undersized at 100. Scheduled reviews ensure your support structure scales with your operation rather than falling behind it.
Conclusion
Market access is a function where strategic decisions have enormous commercial and patient impact, but where day-to-day operations require specialized expertise far removed from the CEO’s optimal focus. Building capable market access leadership, establishing clear pricing governance, and maintaining CEO engagement at strategic inflection points produces the best outcomes.
Set the pricing strategy. Delegate the negotiations. Monitor the access outcomes.
For pharmaceutical market access and pricing strategy insights, visit McKinsey.com/industries/life-sciences.